Europe Early Toxicity Testing Market by Technique Type (In Vivo, In Vitro, and In Silico), by Application (Drug discovery, Chemical testing and Others) and End Users (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3487
- Pages: 181
-
Format:
The Europe early toxicity testing market accounted for $265 million in 2017, and is expected to reach $460 million by 2025, registering a CAGR of 7.1% from 2018 to 2025.
Toxicity is the degree of threat posed by a substance to the living organism, and toxicology is a branch of science that deals with measurement and further analysis of these chemical substances and their adverse effects on the body of an organism. The effects of chemical substances on the body are studied to choose a potential drug candidate during the development of newer molecules. Early toxicity testing is carried out at preclinical stages of a drug development process and is essential as toxicity serves as the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. Early toxicity testing can be performed using different techniques such as in vivo, in vitro, and in silico. These techniques are employed to carry out different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others.
Major factors that drive the market growth are surge in the research and development activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in the Europe early toxicity testing industry and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the Europe early toxicity testing market on the basis of technique, application, end users, and country to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on country, the market is studied across different countries of Europe such as Germany, France, the UK, and rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Europe early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the European market.
KEY MARKET SEGMENTS
By Technique
o In Vivo
o In Vitro
In Vitro Toxicity Testing Market by Assays
Enzyme Toxicity Assays
Bacterial Toxicity Assays
Cell-Based ELISA and Western Blots
Tissue Culture Assays
Receptor Binding Assays
Other Assays
In Vitro Toxicity Testing Market by Toxicity Endpoints
Dermal Toxicity
Systemic Toxicity
Carcinogenicity
Ocular Toxicity
Skin Sensitization and Irritation
Genotoxicity
Neurotoxicity
Organ Toxicity
Other Toxicity Endpoints
o In Silico
By Application
o Drug discovery
o Chemical testing
o Others
By End User
o Pharmaceuticals Industry
o Food Industry
o Chemicals Industry
o Cosmetics Industry
o Other Industries
By Country
o Germany
o France
o UK
o Rest of Europe
LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)
Agilent Technologies, Inc.
General Electric Company (GE Healthcare)
Danaher Corporation (Beckman Coulter, Inc.)
Evotec AG (Cyprotex)
Bioanalytical Systems, Inc.
Bruker Corporation
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
The Jackson Laboratory
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Randox Toxicology
Geneva Laboratories, Inc.
Advanced Chemistry Development (ACD/Labs)
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Government Regulations
3.6. Market Dynamics
3.6.1. Drivers
3.6.1.1. Surge in research and development activities in healthcare
3.6.1.2. Rise in adoption of vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraints
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunities
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact Analyses
CHAPTER 4: EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. In Vitro Early Toxicity Testing Market, By Assay
4.3.3.1. Enzyme toxicity assays
4.3.3.1.1. Market size and forecast
4.3.3.2. Bacterial toxicity assays
4.3.3.2.1.1. Market size and forecast
4.3.3.3. Cell-Based ELISA and Western Blots
4.3.3.3.1.1. Market size and forecast
4.3.3.4. Tissues Culture Assays
4.3.3.4.1.1. Market size and forecast
4.3.3.5. Receptor Binding Assays
4.3.3.5.1.1. Market size and forecast
4.3.3.6. Other Assays
4.3.3.6.1.1. Market size and forecast
4.3.4. In Vitro Early Toxicity Testing Market, By Toxicity End-Points
4.3.4.1. Dermal Toxicity
4.3.4.1.1.1. Market size and forecast
4.3.4.1.1.2. Market size and forecast, by end user
4.3.4.2. Systemic toxicity
4.3.4.2.1.1. Market size and forecast
4.3.4.2.1.2. Market size and forecast, by end user
4.3.4.3. Carcinogenicity
4.3.4.3.1.1. Market size and forecast
4.3.4.4. Ocular toxicity
4.3.4.4.1.1. Market size and forecast
4.3.4.4.1.2. Market size and forecast, by end user
4.3.4.5. Skin sensitization and irritation
4.3.4.5.1.1. Market size and forecast
4.3.4.6. Genotoxicity
4.3.4.6.1.1. Market size and forecast
4.3.4.7. Neurotoxicity
4.3.4.7.1.1. Market size and forecast
4.3.4.8. Organ toxicity
4.3.4.8.1.1. Market size and forecast
4.3.4.9. Other toxicity endpoints
4.3.4.9.1.1. Market size and forecast
4.4. In Silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Medical
5.2.1. Market size and forecast, by type
5.2.1.1. Examination
5.2.1.1.1. Market size and forecast
5.2.1.2. Surgical
5.2.1.2.1. Market size and forecast
5.2.2. Market size and forecast, by country
5.3. Non-Medical
5.3.1. Market size and forecast, by type
5.3.1.1. Food services
5.3.1.1.1. Market size and forecast
5.3.1.2. Clean Room
5.3.1.2.1. Market size and forecast
5.3.1.3. Industrial
5.3.1.3.1. Market size and forecast
5.3.2. Market size and forecast, by country
CHAPTER 6: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical Industry
6.2.1. Market size and forecast, by country
6.3. Diagnostics Industry
6.3.1. Market size and forecast, by country
6.4. Food Industry
6.4.1. Market size and forecast, by country
6.5. Chemicals Industry
6.5.1. Market size and forecast, by country
6.6. Cosmetic Industry
6.6.1. Market size and forecast, by country
6.7. Other Industries
6.7.1. Market size and forecast, by country
CHAPTER 7: EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
7.1. Overview
7.1.1. Key market trends, growth factors, and opportunities
7.1.2. Market size and forecast, by country
7.1.2.1. Germany
7.1.2.1.1. Germany market size and forecast, by technique
7.1.2.1.2. Germany market size and forecast, by application
7.1.2.1.3. Germany market size and forecast, by end user
7.1.2.2. France
7.1.2.2.1. France market size and forecast, by technique
7.1.2.2.2. France market size and forecast, by application
7.1.2.2.3. France market size and forecast, by end user
7.1.2.3. UK
7.1.2.3.1. UK market size and forecast, by technique
7.1.2.3.2. UK market size and forecast, by application
7.1.2.3.3. UK market size and forecast, by end user
7.1.2.4. Rest of Europe
7.1.2.4.1. Rest of Europe market size and forecast, by technique
7.1.2.4.2. Rest of Europe market size and forecast, by application
7.1.2.4.3. Rest of Europe market size and forecast, by end user
7.1.3. Market size and forecast, by technique
7.1.4. Market volume and forecast, by application
7.1.5. Market volume and forecast, by end user
CHAPTER 8: COMPANY PROFILES, KEY MANUFACTURERS
8.1. Agilent Technologies, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product type Portfolio
8.1.5. Business performance
8.2. General Electric Company (GE Healthcare)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Danaher Corporation (Beckman Coulter, Inc.)
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product type portfolio
8.3.5. Business performance
8.4. Evotec AG (Cyprotex)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Bioanalytical Systems, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. BRUKER CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. PerkinElmer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. The Jackson Laboratory
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Business performance
8.10. Thermo Fisher Scientific, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. BUSINESS PERFORMANCE
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
